1.18

4.84% -0.06

Marker Therapeutics Inc (MRKR)

Overview News Price History Financials Discussions Forecast Stock Split

Marker Therapeutics Inc stock is traded at $1.18, with a volume of 35,306. It is down -4.84% in the last 24 hours and down -4.07% over the past month. Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from MAR-T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells. These T cells are designed to recognize multiple tumor targets to produce broad spectrum anti-tumor activity. Its pipeline products include: Autologous MAR-T cell product for the treatment of lymphoma and pancreatic cancer (MT-601), and Off-the-Shelf (OTS) products (MT-401-OTS).

Previous Close:

$1.24

Open:

$1.25

24h Volume:

35,306

Relative Volume:

0.57

Market Cap:

$19.67M

Revenue:

$3.20M

Net Income/Loss:

$-10.90M

P/E Ratio:

-1.7513

EPS:

-0.6738

Net Cash Flow:

$-7.92M

1W Performance:

-13.87%

1M Performance:

-4.07%

6M Performance:

-18.06%

1Y Performance:

+37.24%

1-Day Range:

$1.18

$1.3099

1-Week Range:

$1.18

$1.405

52-Week Range:

$0.83

$2.46

Marker Therapeutics Inc Stock (MRKR) Company Profile

Name

Marker Therapeutics Inc

Sector

Healthcare (1074)

Industry

Biotechnology (600)

Phone

(713) 400-6400

Address

2450 HOLCOMBE BLVD, HOUSTON, TX

Employee

Twitter

@MRKRTherapeutic

Next Earnings Date

2026-08-13

Latest SEC Filings

MRKR's Discussions on Twitter

Compare MRKR vs VRTX, REGN, ARGX, MRNA, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
MRKR Marker Therapeutics Inc	1.18	20.34M	3.20M	-10.90M	-7.92M	-0.6738
VRTX Vertex Pharmaceuticals Inc	546.12	136.93B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	827.72	85.11B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	1,033.15	64.95B	4.16B	1.29B	734.26M	19.58
MRNA Moderna Inc	145.55	53.23B	2.23B	-3.19B	-1.60B	-8.1462
RVMD Revolution Medicines Inc	210.02	45.38B	742.00K	-1.37B	-1.07B	-7.0731

Marker Therapeutics Inc Stock (MRKR) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-05-25	Initiated	Canaccord Genuity	Buy
Mar-25-21	Initiated	Piper Sandler	Overweight
Mar-19-21	Initiated	Cantor Fitzgerald	Overweight
May-12-20	Downgrade	Piper Sandler	Overweight → Neutral
May-30-19	Initiated	ROTH Capital	Buy
Mar-01-19	Initiated	Janney	Buy
Dec-03-18	Upgrade	Piper Jaffray	Neutral → Overweight

View All

Marker Therapeutics Inc Stock (MRKR) Latest News

Aug 21, 2026

H.C. Wainwright reiterates Marker Therapeutics stock rating at buy By Investing.com - Investing.com India

Aug 21, 2026

Aug 18, 2026

US High Growth Tech Stocks To Watch In August 2026 - simplywall.st

Aug 18, 2026

Aug 17, 2026

Marker Therapeutics (MRKR) Rises 1.75%, Holding Above Key $1.10 SupportIchimoku Kumo Twist - vinanet.vn

Aug 17, 2026

Aug 14, 2026

Marker Therapeutics Stock Price Forecast. Should You Buy MRKR? - StockInvest.us

Aug 14, 2026

Marker Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView

Aug 14, 2026

MRKR Advances 2.7% to $1.14 as Biotech Stock Holds Above Key SupportVanna Flow - Vinanet

Aug 14, 2026

Marker Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com

Aug 14, 2026

Aug 13, 2026

CCORF Maintains Marker Therapeutics(MRKR.US) With Buy Rating, Maintains Target Price $8 - Moomoo

Aug 13, 2026

Aug 12, 2026

Stock List: Research Stocks from Around the World - GuruFocus

Aug 12, 2026

Aug 10, 2026

Marker Therapeutics Inc expected to post a loss of 22 cents a shareEarnings Preview - TradingView

Aug 10, 2026

Aug 07, 2026